King's College London

Research portal

Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation

Research output: Contribution to journalReview articlepeer-review

Tahseen A. Chowdhury, Mona Wahba, Ritwika Mallik, Javeria Peracha, Dipesh Patel, Parijat De, Damian Fogarty, Andrew Frankel, Janaka Karalliedde, Patrick B. Mark, Rosa M. Montero, Ana Pokrajac, Sagen Zac-Varghese, Stephen C. Bain, Indranil Dasgupta, Debasish Banerjee, Peter Winocour, Adnan Sharif

Original languageEnglish
Article numbere14523
JournalDiabetic Medicine
Volume38
Issue number6
DOIs
Accepted/In press2021
PublishedJun 2021

Bibliographical note

Funding Information: Tahseen A. Chowdhury—None; Mona Wahba—None; Ritwika Mallik—None; Javeria Peracha—None; Dipesh Patel—has received honoraria for advisory work and/or lecture fees from AstraZeneca, Boehinger Ingelheim Eli Lilly, MSD and Napp Pharmaceuticals, Novo Nordisk and Sanofi; Parijat De—has received speaker honoraria from Novo Nordisk, Lilly, Sanofi, Napp, Boehringer‐Ingelheim, Astra and Pfizer; Damian Fogarty—declares speaker honoraria from Vifor, Napp and Pharmacosmos; Andrew Frankel—declares receipt of research grants, preparation of educational materials and attendance at drug advisory boards for Astra‐Zeneca, Boehringer Ingelheim/Lilly Alliance, Merck‐Sharpe and Dohme, Napp Pharmaceuticals Ltd and Novo Nordisk; Janaka Karralliedde—has received honoraria for delivering educational meetings and/or attending advisory boards Boehringer Ingelheim, Astra Zeneca, Sanofi, Janssen and Novo Nordisk. Research grants from: Astra Zeneca and Sanofi; Patrick B. Mark—reports speaker honoraria from Vifor, Astrazeneca, Janssen, Napp and Novartis; research grants from Boehringer Ingelheim and non‐financial support from Pharmacosmos; Rosa M Montero—None; Ana Pokrajac—non‐promotional speaker fees, advisory boards and conference attendance by NAPP and NovoNordisk and Ellie Lily‐BI Alliance; Sagen Zac‐Varghese—None; Steve C. Bain—reports honoraria, teaching and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi‐Aventis, funding for development of educational programs from Cardiff University & Medscape. He owns a share of Glycosmedia and has provided expert advice to the All‐Wales Medicines Strategy Group and National Institute for Health and Care Excellence (NICE) UK; Indranil Dasgupta—None; Debasish Banerjee—None; Peter Winocour—has received honoraria for delivering educational meetings and/or attending advisory boards for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Napp, Sanofi, Novo and Vifor Pharmaceuticals; Adnan Sharif—reports advisory boards for Boehringer Ingelheim, Eli Lilly, Sandoz, Astellas, Atara Biotherapeutics, Novartis, honoraria and grant funding from Chesi, Napp Pharamceuticals, Eli Lilly and travel reimbursement from Sandoz, Novartis. Publisher Copyright: © 2021 Diabetes UK Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

Post-transplant diabetes mellitus (PTDM) is common after solid organ transplantation (SOT) and associated with increased morbidity and mortality for allograft recipients. Despite the significant burden of disease, there is a paucity of literature with regards to detection, prevention and management. Evidence from the general population with diabetes may not be translatable to the unique context of SOT. In light of emerging clinical evidence and novel anti-diabetic agents, there is an urgent need for updated guidance and recommendations in this high-risk cohort. The Association of British Clinical Diabetologists (ABCD) and Renal Association (RA) Diabetic Kidney Disease Clinical Speciality Group has undertaken a systematic review and critical appraisal of the available evidence. Areas of focus are; (1) epidemiology, (2) pathogenesis, (3) detection, (4) management, (5) modification of immunosuppression, (6) prevention, and (7) PTDM in the non-renal setting. Evidence-graded recommendations are provided for the detection, management and prevention of PTDM, with suggested areas for future research and potential audit standards. The guidelines are endorsed by Diabetes UK, the British Transplantation Society and the Royal College of Physicians of London. The full guidelines are available freely online for the diabetes, renal and transplantation community using the link below. The aim of this review article is to introduce an abridged version of this new clinical guideline (https://abcd.care/sites/abcd.care/files/site_uploads/Resources/Position-Papers/ABCD-RA%20PTDM%20v14.pdf).

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454